vs
Side-by-side financial comparison of ASTRAZENECA PLC (AZN) and ORGANIGRAM GLOBAL INC. (OGI). Click either name above to swap in a different company.
ASTRAZENECA PLC is the larger business by last-quarter revenue ($14.5B vs $39.6K, roughly 364730.0× ORGANIGRAM GLOBAL INC.). ASTRAZENECA PLC runs the higher net margin — 16.9% vs -192.9%, a 209.8% gap on every dollar of revenue.
AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Organigram Global Inc. is a leading Canadian producer of high-quality recreational and medical cannabis products. It offers a diverse portfolio of dried flower, edibles, vape products and pre-rolls, primarily serving the domestic Canadian market while expanding operations in select international markets including parts of Europe.
AZN vs OGI — Head-to-Head
Income Statement — Q2 2025 vs Q3 2022
| Metric | | |
|---|---|---|
| Revenue | $14.5B | $39.6K |
| Net Profit | $2.4B | $-76.5K |
| Gross Margin | 82.9% | — |
| Operating Margin | 24.3% | -128.4% |
| Net Margin | 16.9% | -192.9% |
| Revenue YoY | 11.7% | — |
| Net Profit YoY | 27.0% | — |
| EPS (diluted) | $1.57 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $14.5B | — | ||
| Q2 24 | $12.9B | — | ||
| Q2 23 | $11.4B | — | ||
| Q2 22 | $10.8B | $39.6K |
| Q2 25 | $2.4B | — | ||
| Q2 24 | $1.9B | — | ||
| Q2 23 | $1.8B | — | ||
| Q2 22 | $360.0M | $-76.5K |
| Q2 25 | 82.9% | — | ||
| Q2 24 | 83.1% | — | ||
| Q2 23 | 82.8% | — | ||
| Q2 22 | 72.2% | — |
| Q2 25 | 24.3% | — | ||
| Q2 24 | 21.2% | — | ||
| Q2 23 | 21.5% | — | ||
| Q2 22 | 5.0% | -128.4% |
| Q2 25 | 16.9% | — | ||
| Q2 24 | 14.9% | — | ||
| Q2 23 | 15.9% | — | ||
| Q2 22 | 3.3% | -192.9% |
| Q2 25 | $1.57 | — | ||
| Q2 24 | $1.24 | — | ||
| Q2 23 | $1.17 | — | ||
| Q2 22 | $0.23 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.1B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $44.8B | — |
| Total Assets | $112.4B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $7.1B | — | ||
| Q2 24 | $6.9B | — | ||
| Q2 23 | $5.7B | — | ||
| Q2 22 | $4.8B | — |
| Q2 25 | $44.8B | — | ||
| Q2 24 | $39.6B | — | ||
| Q2 23 | $37.4B | — | ||
| Q2 22 | $36.0B | — |
| Q2 25 | $112.4B | — | ||
| Q2 24 | $104.3B | — | ||
| Q2 23 | $96.5B | — | ||
| Q2 22 | $96.6B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-15.2K |
| Free Cash FlowOCF − Capex | — | $-19.9K |
| FCF MarginFCF / Revenue | — | -50.2% |
| Capex IntensityCapex / Revenue | — | 11.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | $-15.2K |
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | $-19.9K |
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | -50.2% |
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | 11.8% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AZN
Segment breakdown not available.
OGI
| Unrealized gain on changes in fair value of biological assets (Note 7) | $20.1K | 51% |
| Other | $19.6K | 49% |
